USPTO Examiner WORSHAM JESSICA N - Art Unit 1615

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18799983COMPOSITION AND METHOD FOR TREATING HEARING LOSSAugust 2024April 2025Allow811YesNo
18777570METHODS FOR PREPARING PRODUCTS FOR TREATING SCALD INFECTION CAUSED BY PSEUDOMONAS AERUGINOSAJuly 2024January 2025Allow610YesNo
18760549COMPOSITIONS AND METHODS FOR SUNLESS TANNINGJuly 2024January 2025Allow620YesNo
18660021NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITIONMay 2024May 2025Allow1220YesNo
18655687COMPOSITIONS AND DOSAGE FORMS FOR ORAL DELIVERYMay 2024June 2025Allow1310YesNo
18620329IMPLANTABLE DEPOTS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTSMarch 2024February 2025Allow1110YesNo
18592160SOLID SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONSFebruary 2024March 2025Abandon1310NoNo
18425556Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancerJanuary 2024April 2025Allow1420YesNo
18576171USE OF A VEGETABLE EXTRACT FROM SALVIA HAENKEI AS AN ACTIVE AGENT IN THE TREATMENT OF HEART DISEASESJanuary 2024March 2025Allow1420NoNo
18543854CROSS LINKED SILK-HYALURONIC ACID COMPOSITIONDecember 2023March 2025Abandon1510NoNo
18562492COMPOSITION COMPRISING AN ESTER OF ALPHA-TOCOPHEROL FOR REDUCING THE RISK OF PRETERM BIRTHNovember 2023July 2025Allow1940YesNo
18467953METHODS OF TREATING ENDOMETRIAL CANCER USING HEMP EXTRACTSeptember 2023November 2024Allow1410YesNo
18240488ANTIMICROBIAL BANDAGEAugust 2023December 2024Allow1620YesNo
18351711Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic ParticlesJuly 2023August 2024Allow1310YesNo
18265903ANTI-OBESITY POTENTIAL OF BISDEMETHOXYCURCUMIN COMPOSITIONSJune 2023February 2025Abandon2010NoNo
18200980BENDAMUSTINE PHARMACEUTICAL COMPOSITIONSMay 2023July 2024Abandon1410NoNo
18319948TOPICAL TREATMENT FOR ANIMALSMay 2023August 2024Abandon1501NoNo
18305051METHODS FOR FABRICATING ISOLATED MICRO- OR NANO-STRUCTURES USING SOFT OR IMPRINT LITHOGRAPHYApril 2023May 2024Abandon1310NoNo
18295670PHARMACEUTICAL FORMULATIONApril 2023May 2024Allow1310YesNo
18021165NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITIONFebruary 2023May 2025Allow2720YesNo
18154419Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancerJanuary 2023November 2023Allow1010YesNo
18082275Compositions for the Treatment of Dry Eye and Methods of Use ThereofDecember 2022February 2025Abandon2621YesNo
18059270THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USES THEREOFNovember 2022April 2024Allow1610NoNo
18070021Self-Neutralizing Amino Acid Based Cationic CompositionsNovember 2022November 2024Allow2330YesNo
17984001COMPOSITIONS AND METHODS OF ADMINISTERING BACLOFENNovember 2022February 2024Allow1510YesNo
18050021METHODS OF TREATING ENDOMETRIAL CANCER USING HEMP EXTRACTOctober 2022September 2023Allow1011YesNo
17966916Composition and method of treatment of elevated ApoE gene expression related health issuesOctober 2022February 2023Allow411YesNo
17966901Composition and method of treatment of health issues related to estrogen metabolism with elevated risk factors in femalesOctober 2022February 2023Allow411YesNo
18046002Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic ParticlesOctober 2022June 2023Allow810NoNo
17917774LOW ENDOTOXIN GELATIN-(METH)ACRYLOYLOctober 2022April 2025Allow3011YesNo
17942396METHOD OF IDENTIFYING AND TREATING PREMATURE INFANTS AT RISK FOR BPDSeptember 2022January 2024Allow1710YesNo
17823020COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDESAugust 2022March 2024Allow1910NoNo
17812479Lapatinib particles and uses thereofJuly 2022January 2024Allow1821YesNo
17784575MINERAL SUPPLEMENTS FOR RUMINANT NUTRITIONJune 2022March 2025Allow3321NoNo
17745923Pouches Comprising Oral Care Active AgentsMay 2022April 2024Abandon2330NoNo
17738803THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUSMay 2022April 2023Allow1110NoNo
17719912ELECTRONIC VAPOR LIQUID COMPOSITION AND METHOD OF USE IN A DISPENSERApril 2022September 2024Abandon2941YesNo
17713069CROSS LINKED SILK-HYALURONIC ACID COMPOSITIONApril 2022December 2023Abandon2120NoNo
17703955COMBINATION OF 25-HYDROXYVITAMIN D AND ANTIOXIDANTS/ANTI-INFLAMMATORIES FOR POULTRY OVARIAN HEALTHMarch 2022March 2024Allow2430NoNo
17685830PHARMACEUTICAL COMPOSITIONS OF PIMOBENDANMarch 2022September 2024Allow3140YesNo
17680970COMPOSITION FOR TREATMENT OF TOPICAL DERMATOLOGICAL BACTERIAL SKIN CONDITIONSFebruary 2022August 2024Allow2910NoNo
17628191ANTI-COCCIDIAL PHYTOGENIC FORMULATIONSJanuary 2022May 2025Abandon4020NoNo
17596647PROTEIN-MODIFIED PLGA MICROSPHERE AND TISSUE-ENGINEERED NERVE CONSTRUCTED THEREWITHDecember 2021August 2023Allow2020YesNo
17644069CENTRAL NERVOUS SYSTEM HEALTH SUPPLEMENTDecember 2021May 2025Allow4110NoNo
17546640EDDS CHELATED NANOCERIA WITH CATALASE-LIKE ACTIVITYDecember 2021May 2023Allow1710YesNo
17540695KETAMINE TRANSDERMAL DELIVERY SYSTEMDecember 2021February 2024Abandon2610NoNo
17532874BENDAMUSTINE PHARMACEUTICAL COMPOSITIONSNovember 2021March 2023Allow1510YesNo
17612100CANNABINOID-COMPRISING COMPOSITIONS FOR MANAGEMENT OF PAINNovember 2021May 2025Abandon4201NoNo
17525298COMPOSITIONS AND METHODS OF ADMINISTERING BACLOFENNovember 2021August 2022Allow920NoNo
17454320IMPLANTABLE DEPOTS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTSNovember 2021March 2024Allow2810YesNo
17595019ANTI-CANCER GOLD COMPOUNDSNovember 2021September 2024Allow3410NoNo
17604133NON-AQUEOUS DRIFT CONTROL SUSPENSIONSOctober 2021July 2025Allow4521YesNo
17499648METHODS FOR TREATING CHEMORESISTANT CANCER-INITIATING CELLSOctober 2021April 2024Abandon3001NoNo
17497819HIGHLY TRANSPARENT WATER CONTINUOUS DENSE NANOLIPID FLUID (DNLF) DISPERSIONS AND METHOD OF PREPARATION USING A TWIN SCREW EXTRUDEROctober 2021December 2024Allow3831YesNo
17480948COMPOSITIONS AND METHODS FOR DECREASING, OR PREVENTING OR REVERSING GAIN OF, SKIN PIGMENTATION IN A MAMMALIAN SUBJECTSeptember 2021December 2023Allow2720YesNo
17472819NANOPARTICLES CARRYING ANTIBIOTICSSeptember 2021November 2023Allow2610NoNo
17471475ELECTRONIC VAPOR LIQUID COMPOSITION AND METHOD OF USESeptember 2021March 2023Abandon1801NoNo
17461713Methods for the preparation of biologically active compounds in nanoparticulate formAugust 2021December 2023Abandon2811NoNo
17432840METHODS AND USES OF NATURAL BASED COMPOSITIONSAugust 2021November 2024Abandon3901NoNo
17432904SAFE PARTICLES FOR THE INTRODUCTION OF USEFUL CHEMICAL AGENTS IN THE BODY WITH CONTROLLED ACTIVATIONAugust 2021January 2024Abandon2901NoNo
17401178SYSTEMS AND METHODS FOR FEEDING SUGAR ALCOHOL TO RUMINANTS DURING PERIODS OF HEAT STRESSAugust 2021January 2023Allow1710YesNo
17381786Lapatinib particles and uses thereofJuly 2021July 2022Abandon1211NoNo
17422958SKIN ENGAGING MEMBER FOR RAZOR CARTRIDGEJuly 2021February 2025Abandon4331NoNo
17373496METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTSJuly 2021December 2024Allow4130YesYes
17363061DENTAL DESENSITIZERJune 2021March 2024Allow3300YesNo
17305009THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USES THEREOFJune 2021September 2022Allow1500YesNo
17362129OMEGA-3 FATTY ACID ESTER COMPOSITIONSJune 2021April 2023Abandon2110NoNo
17343900ORAL DOSAGE FORMS OF IBRUTINIBJune 2021March 2022Allow910YesNo
17333629Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancerMay 2021September 2022Allow1600YesNo
17315804Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic ParticlesMay 2021September 2022Allow1600YesNo
17242030DISCONTINUOUS GUMMY DELIVERY SYSTEMSApril 2021November 2024Abandon4341YesNo
17288310COMPOSITION THAT FORMS LIQUID CRYSTALLINE PARTICLESApril 2021September 2024Abandon4010NoNo
17236055ANTIMICROBIAL AGENTApril 2021February 2023Allow2210NoNo
17286396METHODS FOR TREATING A SUBTYPE OF SMALL CELL LUNG CANCERApril 2021January 2025Abandon4511NoNo
17225218Structured Rheological Solid Personal Care CompositionApril 2021December 2024Abandon4541NoNo
17279551NANO-LIPID CARRIER FOR ENCAPSULATION OF BIOACTIVE MATERIAL, AND METHOD FOR PRODUCING SAMEMarch 2021September 2023Allow3021YesNo
17279067LIPID BARRIER REPAIRMarch 2021February 2024Allow3530YesNo
17203639THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USES THEREOFMarch 2021May 2021Allow200YesNo
17275665Capsule, Tablet or PillMarch 2021August 2022Abandon1710NoNo
17190628MEDICAL GELS CONTAINING A QUATERNARY AMMONIUM COMPOUND, PHENOXYETHANOL, ALOE VERA JUICE, AND NATURAL SPORICIDAL MOISTURIZERSMarch 2021February 2023Abandon2410NoNo
17189973MOLECULAR HYDROGEN-CONTAINING COMPOSITION FOR PREVENTION AND/OR IMPROVEMENT OF GENETIC DISORDERMarch 2021March 2023Abandon2410NoNo
17186442PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASEFebruary 2021September 2024Allow4311NoNo
17181671ELECTROSPUN STRUCTURES HAVING A PHARMACEUTICAL AND METHODS OF MAKING AND USING THE SAMEFebruary 2021August 2023Abandon3021NoNo
17248949IMPLANTABLE DEPOTS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTSFebruary 2021October 2021Allow820YesNo
17170231Composition and Method for Transdermal Delivery of Cannabidiol (CBD) and 9-Tetrahydrocannabinol (THC)February 2021July 2022Allow1721YesNo
17264046SOLID ORAL FORMULATIONS OF AMPHOTERICIN BJanuary 2021July 2022Abandon1710NoNo
17263645SOLID SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONSJanuary 2021March 2024Abandon3730YesNo
17150038INJECTABLE COMPOSITE INKS AND METHODS FOR MAKING AND USING THEREOFJanuary 2021December 2023Allow3520NoNo
17259325FORMULATION OF CANNABINOID COMPOUNDSJanuary 2021September 2024Abandon4401NoNo
17257940TREATMENT AND PREVENTION OF INJURY DUE TO RADIATION EXPOSUREJanuary 2021June 2023Allow2920YesNo
17129519Liquid Micro-Dosing Product Containing an Effective Amount of Cannabis and Process for Making the SameDecember 2020April 2023Abandon2701NoNo
17104170MACROMOLECULAR SYSTEM FOR DELIVERY OF EXOGENOUS ACTIVE SUBSTANCES WITH IMMUNE TRAP TO AVOID NEUTRALIZATION THEREOFNovember 2020February 2023Abandon2701NoNo
17102125IMPLANTABLE DRUG ELUTING SYSTEM AND METHOD OF USENovember 2020August 2024Abandon4481YesNo
16952139AND IMPROVED SKINCARE PRODUCTSNovember 2020March 2025Abandon5221NoNo
17057093PHARMACEUTICAL COMPOSITION OF TAMSULOSIN AND DUTASTERIDENovember 2020June 2023Allow3131YesNo
16951996MICRONUTRIENT SUPPLEMENTSNovember 2020December 2024Abandon4930NoYes
17097039PHARMACEUTICAL COMPOSITIONS OF PIMOBENDANNovember 2020December 2021Allow1300NoNo
17095301METHODS FOR FABRICATING ISOLATED MICRO- OR NANO-STRUCTURES USING SOFT OR IMPRINT LITHOGRAPHYNovember 2020December 2022Allow2520YesNo
17054272COMPOSITIONS AND DOSAGE FORMS FOR ORAL DELIVERYNovember 2020February 2024Allow3930NoYes
17092150TOPICAL TREATMENT FOR ANIMALSNovember 2020January 2023Allow2711YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WORSHAM, JESSICA N.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
17
Examiner Affirmed
12
(70.6%)
Examiner Reversed
5
(29.4%)
Reversal Percentile
44.9%
Lower than average

What This Means

With a 29.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
108
Allowed After Appeal Filing
27
(25.0%)
Not Allowed After Appeal Filing
81
(75.0%)
Filing Benefit Percentile
30.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner WORSHAM, JESSICA N - Prosecution Strategy Guide

Executive Summary

Examiner WORSHAM, JESSICA N works in Art Unit 1615 and has examined 719 patent applications in our dataset. With an allowance rate of 56.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.

Allowance Patterns

Examiner WORSHAM, JESSICA N's allowance rate of 56.5% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WORSHAM, JESSICA N receive 2.44 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WORSHAM, JESSICA N is 29 months. This places the examiner in the 44% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +60.7% benefit to allowance rate for applications examined by WORSHAM, JESSICA N. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.2% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 38.9% of cases where such amendments are filed. This entry rate is in the 52% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 121.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 82% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 77.0% of appeals filed. This is in the 64% percentile among all examiners. Of these withdrawals, 57.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 49.4% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 58% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.